Oxford BioDynamics (LSE:OBD) has entered the Gulf market for its EpiSwitch PSE prostate cancer blood test through a new commercial partnership with The Dubai London Clinics & Hospitals Group in the United Arab Emirates.
Under the agreement, EpiSwitch PSE will be made available through the healthcare provider’s network of facilities across the UAE. Patient blood samples will be collected locally before being sent to Oxford BioDynamics’ laboratory in the UK for processing and analysis.
The two organisations have already validated the complete clinical workflow, establishing the procedures required to move samples from collection in the UAE through to testing and reporting from the UK laboratory.
Partnership Expands EpiSwitch PSE Into Gulf Region
The agreement represents Oxford BioDynamics’ first commercial partnership for EpiSwitch PSE in the Gulf, extending the company’s international presence in prostate cancer diagnostics.
Oxford BioDynamics and Dubai London Clinics & Hospitals will work together on clinician engagement and development of the local market. The companies aim to increase awareness of the test among healthcare professionals and build testing volumes as adoption develops.
The partnership could also broaden patient access to a more targeted approach to prostate cancer assessment in the UAE, while providing Oxford BioDynamics with an entry point into a potentially significant regional healthcare market.
Successful adoption through the Dubai London Clinics & Hospitals network could provide further commercial validation for EpiSwitch PSE and support the company’s wider strategy of expanding the test into international markets.
Financial Challenges Continue to Weigh on Outlook
Despite progress in commercialising its diagnostic technology, Oxford BioDynamics continues to face financial pressures. The company remains loss-making, while elevated leverage and constrained cash flow contribute to its overall risk profile.
Technical indicators are also generally weak. Although the shares are trading above their 20-day moving average, they remain below longer-term moving averages, suggesting that the broader technical trend remains under pressure.
Valuation metrics offer limited support while earnings remain negative, resulting in a negative price-to-earnings ratio, while no dividend yield is available. Growth in commercial testing volumes and additional partnerships are therefore likely to remain important factors in the company’s longer-term outlook.
More About Oxford BioDynamics
Oxford BioDynamics is an international biotechnology company specialising in precision clinical diagnostics and personalised healthcare.
Its portfolio includes the EpiSwitch PSE blood test for prostate cancer, alongside the EpiSwitch Orion cloud-based 3D genomics platform used by pharmaceutical and biotechnology companies. The business is focused on expanding the application of its EpiSwitch technology across cancer diagnostics and other areas of precision medicine while developing its presence in international healthcare markets.
Leave a Reply